These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39011654)

  • 1. Discovery of candidate biomarkers from plasma-derived extracellular vesicles of patients with cirrhosis and hepatocellular carcinoma: an exploratory proteomic study.
    Zertuche-Martínez C; Velázquez-Enríquez JM; González-García K; Santos-Álvarez JC; Romero-Tlalolini MLÁ; Pina-Canseco S; Pérez-Campos Mayoral L; Muriel P; Villa-Treviño S; Baltiérrez-Hoyos R; Arellanes-Robledo J; Vásquez-Garzón VR
    Mol Omics; 2024 Aug; 20(7):483-495. PubMed ID: 39011654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer.
    Uzzaman A; Zhang X; Qiao Z; Zhan H; Sohail A; Wahid A; Shang Z; Guan X; Cao CX; Xiao H
    Biochimie; 2020 Oct; 177():132-141. PubMed ID: 32835735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.
    Huang Y; Zhou S; Zhu J; Lubman DM; Mechref Y
    Electrophoresis; 2017 Sep; 38(17):2160-2167. PubMed ID: 28543513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma.
    Tsai TH; Song E; Zhu R; Di Poto C; Wang M; Luo Y; Varghese RS; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    Proteomics; 2015 Jul; 15(13):2369-81. PubMed ID: 25778709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.
    Fye HK; Wright-Drakesmith C; Kramer HB; Camey S; Nogueira da Costa A; Jeng A; Bah A; Kirk GD; Sharif MI; Ladep NG; Okeke E; Hainaut P; Taylor-Robinson SD; Kessler BM; Mendy ME
    PLoS One; 2013; 8(7):e68381. PubMed ID: 23935864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysis.
    Paes Leme AF; Yokoo S; Normando AGC; Ormonde JVS; Domingues RR; Cruz FF; Silva PL; Souza BSF; Dos Santos CC; Castro-Faria-Neto H; Martins CM; Lopes-Pacheco M; Rocco PRM
    Cytotherapy; 2024 May; 26(5):444-455. PubMed ID: 38363248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma.
    Dong W; Xia Z; Chai Z; Qiu Z; Wang X; Yang Z; Wang J; Zhang T; Zhang Q; Jin J
    World J Surg Oncol; 2022 Dec; 20(1):387. PubMed ID: 36471393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease.
    Ye B; Shen Y; Chen H; Lin S; Mao W; Dong Y; Li X
    Sci Rep; 2022 Aug; 12(1):14428. PubMed ID: 36002595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic and phosphoproteomic profiling of urinary small extracellular vesicles in hepatocellular carcinoma.
    Li D; Gao Y; Wang C; Hu L
    Analyst; 2024 Aug; 149(17):4378-4387. PubMed ID: 38995156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SILAC-Based Characterization of Plasma-Derived Extracellular Vesicles in Patients Undergoing Partial Hepatectomy.
    Resch U; Hackl H; Pereyra D; Santol J; Brunnthaler L; Probst J; Jankoschek AS; Aiad M; Nolte H; Krueger M; Starlinger P; Assinger A
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma.
    Tsai TH; Wang M; Di Poto C; Hu Y; Zhou S; Zhao Y; Varghese RS; Luo Y; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    J Proteome Res; 2014 Nov; 13(11):4859-68. PubMed ID: 25077556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum protein biomarkers for HCC risk prediction in HIV/HBV co-infected people: a clinical proteomic study using mass spectrometry.
    Ke H; Yuan R; Liu H; Luo M; Hu H; Zhang E; Zhuang K; Yang Y; Yang R
    Front Immunol; 2023; 14():1282469. PubMed ID: 38022651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The trajectory of vesicular proteomic signatures from HBV-HCC by chitosan-magnetic bead-based separation and DIA-proteomic analysis.
    Cao L; Zhou Y; Lin S; Yang C; Guan Z; Li X; Yang S; Gao T; Zhao J; Fan N; Song Y; Li D; Li X; Li Z; Guan F; Tan Z
    J Extracell Vesicles; 2024 Sep; 13(9):e12499. PubMed ID: 39207047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.
    Gray J; Chattopadhyay D; Beale GS; Patman GL; Miele L; King BP; Stewart S; Hudson M; Day CP; Manas DM; Reeves HL
    BMC Cancer; 2009 Aug; 9():271. PubMed ID: 19656391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury.
    Cheow ES; Cheng WC; Lee CN; de Kleijn D; Sorokin V; Sze SK
    Mol Cell Proteomics; 2016 Aug; 15(8):2628-40. PubMed ID: 27234505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
    Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S
    Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS.
    Kang X; Sun L; Guo K; Shu H; Yao J; Qin X; Liu Y
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1151-9. PubMed ID: 20130913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.